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Abstract
Background Levomilnacipran (1S, 2R-milnacipran) is a
potent and selective serotonin (5-HT) and norepinephrine
(noradrenaline) reuptake inhibitor approved for the treat-
ment of major depressive disorder in adults.
Objective The objective of this study was to evaluate the
longer-term safety and tolerability of levomilnacipran
extended-release (ER).
Methods Patients who completed double-blind treatment/
down-taper in one of three lead-in levomilnacipran ER
studies were eligible for this 48-week open-label extension.
Safety evaluations included assessment of treatment-
emergent adverse events (TEAEs), physical examinations,
laboratory and vital sign measures, and suicidality, sum-
marized using descriptive statistics for the safety
population.
Results The completion rate was 47 %; median treatment
duration was 280 days. The most frequent reasons for
discontinuation were withdrawal of consent (14 %) and
adverse events (AEs; 13 %). TEAEs were reported by 712
(86 %) patients; most were mild/moderate and occurred
early in treatment. The most common TEAEs were head-
ache (22 %) and nausea (16 %); 36 (4 %) patients had C1
serious AEs. No clinically meaningful changes occurred in
mean liver enzyme, metabolic, hematologic, urinalysis, or
serum values; potentially clinically significant high AST or
ALT values (C3 9 upper limit of normal) occurred in five
patients. Vital sign changes occurred early and remained
relatively stable. Mean increases for pulse rate (9.1 beats
per minute [bpm]), and supine systolic (3.9 mmHg) and
diastolic (3.3 mmHg) blood pressure were noted. The
increase in the mean QT interval corrected using the Bazett
formula (10.9 ms) was consistent with heart rate increase
(12.8 bpm); there was no meaningful change in mean QT
interval corrected using the Fridericia formula (-1.3 ms).
Other than tachycardia and heart rate increases, ECG-
related TEAEs were low (\0.5 %).
Conclusion No new or inconsistent safety/tolerability
findings were discovered during longer-term evaluation.
1 Introduction
Major depressive disorder (MDD) is a commonly recurrent
and disabling disorder that can disrupt functioning in mul-
tiple domains including work, school, family life, and social
relationships. By 2030, unipolar major depression is pro-
jected to be among the top three causes of global disease
burden [1]. Pharmacologic treatment over an extended per-
iod of time is recommended for many patients with MDD to
reduce the risk of depression recurrence [2] and associated
psychosocial impairment. For pharmacologic treatment to be
effective, adherence to antidepressant medication at the
recommended dose for the recommended duration is critical.
Poor tolerability frequently contributes to issues such as
inadequate dose titration and treatment noncompliance, with
adverse effects commonly cited as the reason antidepressant
medication is discontinued prematurely [3]. As such, it is
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important to assess the safety and tolerability of antide-
pressant agents over long-term treatment.
Levomilnacipran (1S, 2R-milnacipran) is a potent and
selective serotonin (5-HT) and norepinephrine (noradren-
aline) reuptake inhibitor (SNRI) that is approved for the
treatment of MDD in adults. An extended-release (ER)
formulation was developed to allow for once-daily dosing.
Levomilnacipran has approximately twofold greater
potency for inhibition of norepinephrine relative to sero-
tonin reuptake [4]. Potency for inhibition of serotonin re-
uptake relative to norepinephrine reuptake varies among
members of the SNRI class of antidepressants. Duloxetine
is tenfold more potent for serotonin reuptake inhibition
than norepinephrine reuptake inhibition while venlafaxine
and desvenlafaxine show 30-fold higher potency for
inhibiting serotonin versus norepinephrine reuptake [5].
For venlafaxine, meaningful norepinephrine inhibition is
only achieved at high doses [6], so it primarily acts as a
selective serotonin reuptake inhibitor (SSRI) when pre-
scribed at the usual dose of 150 mg/day or less. Compared
with duloxetine [4], venlafaxine [4], or desvenlafaxine [7],
levomilnacipran has over tenfold higher selectivity for
norepinephrine versus serotonin reuptake inhibition.
Since many patients with MDD take multiple medica-
tions, the potential for drug–drug interactions is clinically
relevant. Levomilnacipran is not extensively hepatically
metabolized and is primarily renally excreted unchanged in
urine (approximately 58 % of administered dose) [8].
Cytochrome P450 (CYP) 3A4 oxidizes a broad spectrum of
drugs, including levomilnacipran ER, by a number of
metabolic processes. This may result in pharmacokinetic
interactions between drugs due to CYP3A4 inhibition or
induction. Dose adjustment is recommended when levo-
milnacipran ER is co-administered with strong inhibitors of
CYP3A4 (e.g., ketoconazole); no dose adjustment is nee-
ded when co-administered with a CYP3A4 inducer or
substrate [8, 9].
Short-term efficacy has been previously demonstrated in
four randomized, double-blind studies comparing fixed [10,
11] or flexible doses [12, 13] of levomilnacipran ER to
placebo. In another flexible-dose study, levomilnacipran
ER improved depressive symptoms but did not achieve
statistically significant separation from placebo [14].
Additionally, in a relapse prevention study comparing
levomilnacipran ER and placebo [15], time to relapse was
greater in the levomilnacipran ER group versus placebo,
although the treatment difference was not statistically
significant. Levomilnacipran ER was generally well-toler-
ated in all studies.
The primary objective of this open-label extension study
was to evaluate the longer-term safety and tolerability of
levomilnacipran ER in the treatment of adult patients with
MDD. Although efficacy assessments were collected, they
were not categorized as primary, secondary, or additional
outcomes and inferential statistics were not performed.
2 Methods
This Phase III clinical study (NCT01034267) was con-
ducted between December 2009 and June 2012 at 68 study
centers in the US. The study was in full compliance with
US FDA guidelines for Good Clinical Practice and the
ethical principles of the Declaration of Helsinki. The final
protocol was approved by the appropriate institutional
review board (IRB) for each study site and patients gave
written informed consent for their participation.
2.1 Study Design
This study was a multicenter, open-label, flexible-dose
(40–120 mg/day) extension study of levomilnacipran ER
conducted in adult patients with MDD. Participants were
required to have completed 8 weeks of fixed- or flexible-
dose treatment with levomilnacipran ER or placebo, and
the 2-week double-blind down-taper period in one of three
double-blind lead-in studies. The lead-in studies were
study 1 (NCT00969709; levomilnacipran ER 40, 80, or
120 mg/day or placebo) [10]; study 2 (NCT00969150;
levomilnacipran ER 40–120 mg/day or placebo) [14]; and
study 3 (NCT01034462; levomilnacipran ER 40–120 mg/
day or placebo) [13].
This extension study was 52 weeks in duration and
consisted of a 48-week open-label treatment period fol-
lowed by a down-taper period of up to 4 weeks (Fig. 1);
week 0/visit 1 refers to the last visit of the double-blind
down-taper, which was also the first week of the open-label
study. There were 18 scheduled clinic visits during the
open-label treatment (weeks 0–48) and down-taper (weeks
48–52) periods; visits occurred weekly for the first 4 weeks
and every 4 weeks thereafter. Additionally, 11 interim
telephone contacts were conducted at 2-week intervals
between site visits to evaluate adverse events (AEs) and
concomitant medications.
All patients received levomilnacipran ER 20 mg on days
1 and 2, and 40 mg on days 3–7 of open-label treatment.
After week 1, the dose could be increased in 40-mg
increments at weekly intervals based on the investigator’s
judgment of response and the absence of dose-limiting
AEs. The minimum and maximum allowable dosages were
40 and 120 mg/day, respectively. Following a dose
increase, the dose could be decreased to the previous level
at any time if, in the opinion of the investigator, dose-
limiting AEs developed. Patients completing 48 weeks of
open-label treatment or prematurely discontinuing under-
went a dosage down-taper period of up to 4 weeks if
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medically appropriate. Final dose levels were tapered
by weekly decrements as follows: final 120 mg/day to
80 mg/day, 40 mg/day, 20 mg/day, and 0; final 80 mg/day
to 40 mg/day, 40 mg/day, 20 mg/day and 0; final 40 mg/
day to 20 mg/day, 20 mg/day, 0 and 0.
2.2 Inclusion Criteria
Inclusion criteria for the lead-in studies [10, 13, 14] were
similar and typical of criteria used in clinical studies of
antidepressants for the treatment of MDD. At the lead-in
study screening visit, all patients were between 18 and
80 years of age, inclusive, and met the criteria for MDD
defined by the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition, text revision, (DSM-IV-TR) [16].
Included patients had an ongoing depressive episode of
C4 weeks’ (study 2 and 3) or C8 weeks’ (study 1) duration
and a score C30 on the clinician-rated Montgomery-
A˚sberg Depression Rating Scale (MADRS) [17].
To be included in the extension study, patients had to
have completed double-blind treatment with levomilna-
cipran ER or placebo and the double-blind down-taper
period in one of the lead-in studies. At the screening visit
of the lead-in study, patients had normal physical exami-
nation findings, clinical laboratory test results, and ECG
results, or abnormal results that were judged not clinically
significant by the investigator. Additionally, women of
childbearing potential had a negative serum b-human
chorionic gonadotropin (b-hCG) serum pregnancy test and
a negative urine pregnancy test at week 0 of open-label
treatment.
2.3 Exclusion Criteria
Psychiatric or medical exclusions during the lead-in
studies were similar and typical of exclusions in anti-
depressant clinical trials for MDD. Psychiatric exclusions
included a history of meeting DSM-IV-TR criteria for a
manic/hypomanic episode or depressive episode with
psychotic features, or substance abuse or dependence
within the preceding 6 months (except nicotine or caf-
feine). Medical exclusions included concurrent medical
conditions that might interfere with the conduct of the
study, confound the interpretation of study results, or
endanger the patient’s well-being. Patients were excluded
if they met any of the following criteria for suicide risk:
investigator’s determination of significant risk; a score
C5 on MADRS Item 10 (Suicidal Thoughts) at the final
down-taper period visit of the lead-in study; or signifi-
cant risk based on information collected from patient
interviews and the Columbia-Suicide Severity Rating
Scale (C-SSRS) [18]. Patients requiring prohibited con-
comitant medications were excluded; any concomitant
drug with psychotropic activity, except eszopiclone,
zolpidem, zolpidem ER, or zaleplon for sleep, was
prohibited.
Any exclusionary psychiatric or medical condition that
developed during the lead-in study resulted in exclusion
from the extension study. At week 0 of the open-label
study, patients with any clinically significant, unstable, or
decompensated cardiovascular change or a positive urine
drug screen for alcohol or any other illegal or prohibited
substances were excluded.
Fig. 1 Study design. ER extended-release
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2.4 Safety and Tolerability Measures
Safety assessments were performed at regular intervals.
AEs were spontaneously reported by the patient or identi-
fied by study personnel and coded by the preferred Medical
Dictionary for Regulatory Activities (MedDRA) term
(weeks 0–48 and during down-taper/until 30 days after the
last dose of treatment). AEs were evaluated by the inves-
tigator for intensity (i.e., mild, moderate, or severe) and
possible relationship to treatment (related or not related).
Other evaluations included physical examinations (week
24 and 48), clinical laboratory values (weeks 0, 16, 24, 36,
48), ECGs (weeks 0, 2, 4, 8, 16, 24, 36, 48), and vital sign
assessment (all scheduled visits in weeks 1–48 and down-
taper weeks 50 and 52).
Severity of suicidal ideation and behavior were reported
from C-SSRS evaluations (weeks 1–48 and down-taper
weeks 50 and 52); suicide-related AEs were also examined.
On the C-SSRS, 5-item scales classify the severity of sui-
cidal ideation from 1 (wish to be dead, without intent to
act) to 5 (active suicidal ideation with specific plan and
intent), and suicidal behavior from 0 (no suicidal behavior)
to 4 (actual attempt).
Ongoing AEs and concomitant medications being taken
at the final visit of the double-blind down-taper period of
the lead-in study were transferred to the case report form
for week 0 of the open-label study.
2.5 Efficacy Measures
The primary objective of this study was the evaluation of
long-term safety and tolerability of levomilnacipran ER; as
such, efficacy assessments were collected but not catego-
rized as primary, secondary, or additional outcomes. Col-
lected measures consisted of the MADRS (weeks 0, 2–8,
16, 24, 36, 48), Clinical Global Impressions-Severity
(CGI-S) (weeks 0–48), and Clinical Global Impressions-
Improvement (CGI-I) [19] (weeks 1–48); the CGI-I was
rated with respect to the baseline assessment of the lead-in
study.
2.6 Data Analysis
The enrolled population consisted of all patients who
completed the double-blind and down-taper periods of a
lead-in study and consented to participate in the open-label
extension study of levomilnacipran ER. Safety analyses
were based on the safety population, which consisted of
enrolled patients who had at least one dose of open-label
levomilnacipran ER during the extension study. Patient
disposition was presented by number and percentage for
the safety population; extent of exposure, daily dose, and
safety parameters were summarized using descriptive
statistics. Potentially clinically significant (PCS) high and
low criteria for laboratory values, ECG, and vital signs
were prespecified. Baseline values from the respective
lead-in study were used as the baseline for all analyses of
safety parameters.
Baseline for all efficacy analyses was the corresponding
baseline from the respective lead-in study; change in
MADRS total score was also summarized using week 0 of
the extension study as baseline. Efficacy summaries
included MADRS total score change from baseline (lead-in
study) and week 0 (open-label extension), CGI-S score
change from baseline, CGI-I score, MADRS response
(MADRS score C50 % reduction from baseline) and
remission (MADRS score B10) rates, and CGI-I response
rate (CGI-I score B2). Evaluations were based on the
modified intent-to-treat (ITT) population, which consisted
of all patients in the safety population who had at least one
MADRS total score assessment during the extension study.
No inferential statistical analyses were performed;
descriptive statistics were presented by visit for all efficacy
parameters using the last observation carried forward
(LOCF) approach to impute missing values after week 1,
and the observed cases (OC) approach.
3 Results
3.1 Patient Disposition and Demographic
Characteristics
A total of 828 patients were enrolled in the open-label
extension (enrolled population); 825 patients received at
least one dose of open-label levomilnacipran ER (safety
population) and 813 patients additionally had at least one
post-baseline MADRS assessment during open-label
treatment (ITT population). For patients who entered the
extension study and were included in the safety population,
469 had received levomilnacipran ER in a respective lead-
in study and 356 had received placebo (Table 1).
All patients completed a 2-week double-blind down-
taper before entering the extension study; each patient
received levomilnacipran ER on an identical progressive
dose-titration schedule in the extension study. Patients who
completed 48 weeks of open-label treatment were consid-
ered extension study completers; reasons for discontinua-
tion are presented in Table 2. AEs that led to the
discontinuation of three or more patients were nausea (ten
patients); hyperhidrosis (eight patients); tachycardia (seven
patients); hypertension (six patients); headache (five
patients); suicide attempt (two patients with actual attempts
and two patients with aborted attempts); urinary hesitation
and depression (four patients each); and urinary retention
and blood pressure increase (three patients each).
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Mean (standard deviation [SD]) patient age was 44
(12.8) years and 65 % of the patients were women; mean
body mass index was 29.10 (5.57) kg/m2 (safety popula-
tion). The majority of patients had a history of recurrent
MDD (78 %), with a 12-year mean duration of illness; the
mean (SD) duration of the current episode was 20 (51)
months (median duration 8 months).
At baseline, 54 and 22 % of patients had a lifetime
history of suicidal ideation and suicidal behavior, respec-
tively, as determined by the C-SSRS. No patients were
considered to represent a significant suicide risk at the time
of study enrollment and no patient had made a suicide
attempt within the past year.
3.2 Extent of Exposure
The median duration of treatment was 280 days. The final
daily dose was 40 mg/day for 27 %, 80 mg/day for 26 %,
and 120 mg/day for 47 % of patients. For 0.4 % of
patients, the final daily dose was 20 mg/day; these patients
discontinued the study during the up-titration period but
were included in the safety analysis. Patient-years of
exposure was 502.3.
3.3 Adverse Events
During open-label treatment, 712 (86 %) patients reported
a treatment-emergent AE (TEAE). The number of patients
who discontinued due to AEs in this extension study was
similar for patients who had received double-blind lead-in
placebo (55 patients [11 %]) or levomilnacipran ER (52
patients [15 %]) treatment. The incidence of patients with
at least one TEAE report decreased over time during open-
label treatment (Fig. 2).
The most common TEAEs (C5 % of patients during
open-label treatment) are presented in Table 3. Most TE-
AEs were considered mild (57 %) or moderate (38 %); of
the total number of TEAEs reported (n = 3,408), 49 %
were considered to be possibly or probably related to lev-
omilnacipran ER. Of TEAEs that were considered severe
(5 %), the most common were nausea and headache. Most
TEAEs were transient in nature. Of patients with at least
one TEAE that was considered possibly or probably related
to levomilnacipran ER (n = 557), 35 % had events that
were considered mild and 55 % had events that were
considered moderate in severity.
Pregnancy was reported in three patients during open-
label treatment and resulted in premature discontinuation
Table 1 Lead-in study treatment assignment and final dose for patients who entered the extension study
Lead-in study Placebo Levomilnacipran ER
40 mg/day 80 mg/day 120 mg/day
Study 1 (assigned fixed-dose) 107 97 83 89
Study 2 (final flexible dose) 125 29 23 46
Study 3 (final flexible dose)a 124 26 26 48
ER extended-release
a In study 3, a final daily levomilnacipran ER dose of 20 or 160 mg was inadvertently taken by one patient each; these two patients were not
included in the final dose count
Table 2 Premature discontinuation during extension study (safety
population) of levomilnacipran ER 40–120 mg/day (n = 825)
Patient status n (%)
Completed open-label treatment 384 (46.5)
Prematurely discontinued 441 (53.5)
Reason for discontinuation
Adverse event 107 (13.0)
Insufficient therapeutic response 56 (6.8)
Protocol violation 67 (8.1)
Withdrawal of consent 118 (14.3)
Lost to follow-up 87 (10.5)
Other reasons 6 (0.7)
Entered down-taper perioda 490 (59.4)
ER extended-release
a Patients completing 48 weeks of open-label treatment or prema-
turely discontinuing entered a dosage down-taper period of up to
4 weeks if medically appropriate
Fig. 2 Incidence of patients with C1 treatment-emergent adverse
event over time during open-label treatment (safety population)
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of two of the patients. The patient who did not discontinue
the study prematurely had received treatment for 330 days
and had a positive pregnancy test on day 337. All three
pregnancies resulted in live births with no complications.
During open-label treatment, 36 (4 %) patients had at
least one serious AE (SAE). No deaths occurred during this
study; however, one patient who completed 8 weeks of
placebo treatment in a lead-in study and received open-
label levomilnacipran ER for 224 days was diagnosed with
stage IV gastric adenocarcinoma on day 223. This patient
discontinued from the study and died from the cancer
42 days later; this SAE was not considered by the inves-
tigator to be related to levomilnacipran ER.
SAEs resulted in the discontinuation of 13 (2 %)
patients. SAEs that were considered possibly or probably
related to levomilnacipran ER and resulted in premature
discontinuation from the study occurred in four patients
(angina pectoris/heart rate increased, supraventricular
extrasystoles/tachycardia/ventricular extrasystoles, con-
vulsion/encephalopathy, and mania in one patient each).
SAEs that were considered not related to levomilnacipran
ER and resulted in premature discontinuation occurred in
nine patients (depression, chest pain [unknown etiology],
overdose/suicide attempt, gastric cancer stage IV, pharyn-
geal cellulitis, depression/suicidal ideation, lower limb
fracture, suicidal behavior, and overdose/suicide attempt in
one patient each).
During the down-taper period, 75 (9 %) patients repor-
ted newly emergent AEs. SAEs occurred in three (0.4 %)
patients during this period (colitis, obstructive inguinal
hernia, and spinal operation in one patient each). No SAE
during the down-taper period was considered possibly or
probably related to levomilnacipran ER.
3.4 Baseline to Endpoint: Safety Parameter Changes
Over Time
3.4.1 ALT, AST, and Liver Function Tests
No clinically meaningful mean changes or consistent
trends were noted in any liver enzyme value. The mean
(SD) change from baseline to endpoint was 2.2 (13.4) U/L
for ALT, 2.1 (11.0) U/L for AST, 2.3 (12.9) U/L for
alkaline phosphatase, and -1.0 (3.8) lmol/L for bilirubin.
No patient met Hy’s Law criteria (ALT or AST
C3 9 upper limit of normal [ULN], total bilirubin
[2 9 ULN, and alkaline phosphatase \2 9 ULN) [20].
PCS high AST/ALT values (C3 9 UNL) were noted in
five patients (one ALT, four AST; organ source of enzymes
not determined). No patient met PCS criteria for low
albumin (\0.9 9 ULN), total bilirubin ([1.5 9 ULN), or
alkaline phosphatase (C3 9 ULN). On day 115, one
patient had an AST value of 330 U/L (C5 9 ULN) and
elevated ALT (129 U/L, not PCS); both AST and ALT
normalized while the patient continued open-label treat-
ment and no associated TEAEs were reported. PCS high
liver enzyme laboratory values were reported as TEAEs in
two patients (ALT/AST increased and liver function test
abnormal in one patient each). Neither of these TEAEs was
an SAE or led to study discontinuation and values
decreased to normal levels while patients remained on
levomilnacipran ER in open-label or down-taper treatment.
Elevated, but non-PCS, changes in ALT or AST values
also resulted in the discontinuation of two patients who had
received placebo in the respective lead-in studies. In one
patient, TEAEs of increased AST and ALT occurred during
double-blind down taper in the lead-in study; the patient
subsequently received 124 days of open-label treatment
and was discontinued from the study due to ongoing
increased AST and ALT values that were considered pos-
sibly or probably related to levomilnacipran ER. Addi-
tionally, one patient who received open-label
levomilnacipran ER for 3 days developed a TEAE of
increased AST on day 1 and was discontinued from the
Table 3 Most common treatment-emergent adverse events (C5 % of
patients) during open-label treatment (safety population) of levo-
milnacipran ER 40–120 mg/day (n = 825)
TEAEs n (%) Related to
levomilnacipran
ERa [n (%)]
Patients with C1 TEAE 712 (86.3) 557 (67.5)
Headache 183 (22.2) 116 (14.1)
Nausea 134 (16.2) 100 (12.1)
Upper respiratory tract infection 109 (13.2) 1 (0.1)
Hyperhidrosis 90 (10.9) 86 (10.4)
Constipation 79 (9.6) 61 (7.4)
Nasopharyngitis 70 (8.5) 2 (0.2)
Dizziness 67 (8.1) 54 (6.5)
Insomnia 66 (8.0) 47 (5.7)
Tachycardia 65 (7.9) 63 (7.6)
Dry mouth 59 (7.2) 54 (6.5)
Heart rate increased 55 (6.7) 53 (6.4)
Hypertension 53 (6.4) 35 (4.2)
Back pain 46 (5.6) 3 (0.4)
Erectile dysfunctionb 16 (5.6) 15 (5.2)
Blood pressure increased 44 (5.3) 37 (4.5)
ER extended-release, TEAE treatment-emergent adverse event
a Percentage of safety population with TEAE possibly or probably
related to levomilnacipran ER as determined by investigator
assessment
b Percentage relative to the number of male patients (n = 286)
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study; the AE resolved on day 10 and was considered
related to levomilnacipran ER.
3.4.2 Metabolic Parameters and Clinical Laboratory
Evaluations
No clinically meaningful trends or changes were noted
for mean values of metabolic, hematologic, urinalysis, or
other serum parameters from baseline to endpoint; rela-
tively small proportions of patients shifted from normal
baseline values to low, high, or PCS values for these
parameters.
3.4.3 Vital Signs
In long-term, open-label treatment, vital sign changes
occurred early and values then remained relatively stable
over the course of the study. Increase (mean [SD]) from
baseline to endpoint was noted for pulse rate (9.1
[11.6] beats per minute [bpm]), and supine systolic (3.9
[11.6] mmHg) and diastolic (3.3 [8.8] mmHg) blood
pressure; median increases for pulse rate, systolic blood
pressure, and diastolic blood pressure were 8.0 bpm,
4.0 mmHg, and 2.5 mmHg, respectively. For change in
pulse rate and blood pressure, differences in age (\45, C45
to \60, C60 years), race (black/African American and
other), and sex (male and female) subgroups compared
with the total population were small and not clinically
meaningful. In general, PCS vital signs were noted in
\1 % of patients (Table 4). No patients met PCS criterion
for high systolic blood pressure; PCS criterion for high
diastolic blood pressure was met in 2 % of patients.
Changes in pulse rate, supine systolic blood pressure,
and supine diastolic blood pressure analyzed by final daily
dose are shown in Table 5. Changes in these vital signs by
final daily dose should be interpreted with caution since
levomilnacipran ER dose could be adjusted at any time
during the extension study; as such, the final dose may not
be representative of the dose taken during the entire
extension or for the longest period of time.
Orthostatic hypotension (reduction C20 mmHg in sys-
tolic blood pressure or a reduction of C10 mmHg in dia-
stolic blood pressure while changing from supine to
standing position) occurred in 21.1 % of patients on at least
one occasion during the open-label treatment period.
Overall, levomilnacipran ER was weight neutral through-
out the study, with mean (SD) change in body weight of
-0.55 (4.34) kg from baseline to endpoint (Fig. 3). Weight
change meeting PCS criteria of C7 % increase or C7 %
decrease occurred in 10 and 17 % of patients, respectively.
Vital sign changes from baseline to endpoint were con-
sistent with results from acute studies of levomilnacipran
ER.
3.4.4 Electrocardiography
An increase (mean [SD]) in QT interval corrected for heart
rate using the Bazett formula (QTcB) from baseline to
endpoint of open-label treatment (10.9 [20.9] ms) was
observed; this was consistent with the increase noted in
heart rate (12.8 [12.3] bpm). No meaningful change in
mean QT interval corrected for heart rate using the Fri-
dericia formula (QTcF) (-1.3 [17.4] ms) was observed.
The percentage of patients with ECG-related TEAEs
other than tachycardia and increased heart rate were low
(\0.5 %) and resulted in study discontinuation for three
patients (supraventricular extrasystoles/ventricular extra-
systoles, ECG T-wave inversion, and arrhythmia in one
patient each). SAEs related to ECG abnormalities were
reported in two patients (supraventricular extrasystoles/
ventricular extrasystoles and ventricular extrasystoles in
one patient each). ECG values that met PCS criteria were
noted in three patients: PR interval (C250 ms), QRS
interval (C150 ms), and QTcB ([500 ms) in one patient
each. No patient had a PCS value for QTcF ([500 ms) and
no QTcF-related TEAEs were reported.
3.5 Suicidality
3.5.1 Columbia-Suicide Severity Rating Scale
During open-label treatment, 22 % of patients reported
C-SSRS–based suicidal ideation; the least severe category
of suicidal ideation (wish to be dead, without intent to act)
was the most common ideation category reported (13 %).
Suicidal behavior was reported for three (0.4 %) patients
(one actual attempt and two aborted attempts).
3.5.2 Suicide-Related Adverse Events
A total of eight (1 %) patients had TEAEs associated with
suicidality: suicidal ideation in four patients and suicidal
behavior in four patients (aborted attempt in two patients
and actual attempt in two patients). These suicide-related
TEAEs were reported as an SAE and/or contributed to
premature discontinuation from the study for seven of the
eight patients.
3.6 Efficacy Summary
Efficacy assessments were collected but no inferential
statistics were performed. Improvements observed with
double-blind levomilnacipran ER in the lead-in studies
were sustained during open-label treatment. Decrease in
MADRS score was seen from the baseline of the respective
lead-in study to the beginning of the extension study (week
0), from week 0 to week 48 of the extension trial, and from
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Table 4 Potentially clinically significant vital sign values during the open-label treatment period (safety population) of levomilnacipran ER
40–120 mg/day (n = 822)a
Vital sign, unit PCS criteria n (%)
Supine systolic blood pressure, mmHg High (C180 mmHg and increase C20 mmHg) 0
Low (B90 mmHg and decrease C20 mmHg) 3 (0.4)
Supine diastolic blood pressure, mmHg High (C105 mmHg and increase C15 mmHg) 19 (2.3)
Low (B50 mmHg and decrease C15 mmHg) 1 (0.1)
Supine pulse rate, bpm High (C120 bpm and increase C15 bpm) 4 (0.5)
Low (B50 bpm and decrease C15 bpm) 2 (0.2)
bpm beats per minute, ER extended-release, PCS potentially clinically significant
a Number of patients in safety population (n = 825) with a baseline and at least one postbaseline value
Table 5 Vital sign changes by final daily levomilnacipran extended-release dose
Vital sign parameter Levomilnacipran ER final daily dosea
40 mg/day (n = 223) 80 mg/day (n = 212) 120 mg/day (n = 387)
Pulse rate, bpm
Mean (SD) 8.0 (11.2) 8.3 (12.0) 10.1 (11.4)
Median (min, max) 8.0 (-28, 47) 7.5 (-20, 46) 10.0 (-17, 46)
Supine systolic blood pressure, mmHg
Mean (SD) 3.2 (11.7) 4.2 (11.4) 4.3 (11.7)
Median (min, max) 2.0 (-30, 36) 4.0 (-26, 40) 4.0 (-25, 42)
Supine diastolic blood pressure, mmHg
Mean (SD) 3.2 (8.5) 3.7 (8.9) 3.2 (9.0)
Median (min, max) 2.0 (-20, 28) 4.0 (-18, 24) 2.0 (-17, 39)
bpm beats per minute, ER extended-release, max maximum, min minimum, SD standard deviation
a Levomilnacipran ER dose could be adjusted at any time during the extension study so the final dose may not be representative of the dose taken
during the entire extension or for the longest period of time
Fig. 3 Mean change in body
weight by week (safety
population). Week 0 is also the
final visit of the double-blind
down-taper period of the lead-in
study
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baseline of the lead-in study to week 48 (Table 6).
Decreased scores from baseline were also seen on other
measures of efficacy (Table 6).
The percentage of patients that met criteria for MADRS
response (50 % reduction in lead-in study MADRS base-
line total score) at week 48 was high (LOCF 73 %, OC
88 %); similar response rates were seen using the CGI-I
(CGI-I score B2) (LOCF 75 %, OC 90 %). More than half
of patients achieved remission (MADRS total score B10)
at week 48 (LOCF 53 %, OC 69 %). Rates of response and
remission remained stable from week 24 to week 48 of
open-label treatment.
4 Discussion
This open-label extension study was conducted to evaluate
the longer-term safety and tolerability of levomilnacipran
ER in the treatment of adult patients with MDD. No new or
inconsistent findings were discovered during this long-term
safety evaluation; safety and tolerability outcomes were
consistent with results of short-term treatment studies of
levomilnacipran ER.
The completion rate in this 48-week extension study was
47 %; 13 % of patients discontinued the study due to AEs,
which supports the tolerability of levomilnacipran ER for
longer-term use in the treatment of a major depressive
episode. Although approximately 86 % of patients reported
TEAEs during open-label treatment, the incidence of
patients with C1 TEAE report decreased over time during
open-label treatment and most events were considered mild
or moderate in intensity. Common TEAEs that were con-
sidered to be related to levomilnacipran ER were consistent
with its mechanisms of action. In a study of this duration it
may be expected that depressive symptoms may worsen in
some patients over time; 7 % of patients prematurely dis-
continued this study due to insufficient therapeutic
response.
Since differences in efficacy and tolerability have been
demonstrated among the second-generation antidepressant
medications (e.g., SSRIs, SNRIs) [21], short- and long-
term treatment decisions should be made with safety, tol-
erability, and effectiveness in mind. In this open-label
extension study, longer-term tolerability of levomilnacip-
ran ER was similar to what has been previously observed in
acute studies of levomilnacipran ER [10–14]. The most
common TEAEs, headache (22 %) and nausea (16 %),
were reported more frequently in the extension study by
patients who had been assigned to placebo in the respective
lead-in study. Nausea was reported in 20 % of patients who
received lead-in placebo and 13 % of patients who
received lead-in levomilnacipran ER; headache was
reported by 25 and 20 % of lead-in placebo- and levo-
milnacipran ER-treated patients, respectively. The higher
incidence of these TEAEs in lead-in placebo patients may
reflect the lack of prior exposure to levomilnacipran ER for
placebo patients.
Certain AEs, such as sexual dysfunction and weight
gain, are more frequently associated with poor treatment
adherence and premature discontinuation from antidepres-
sant medication [3]. Although the lack of a formal sexual
dysfunction measure in this study prevents a complete
evaluation of possible sexual AEs, erectile dysfunction was
reported as a TEAE in 6 % of males and there were no
discontinuations from the study due to sexual dysfunction.
The overall weight-neutral profile of levomilnacipran ER
observed in the short-term studies [10–14] was also seen
with longer-term use in the extension study. A small mean
Table 6 Efficacy assessments
(intent-to-treat population) of
levomilnacipran ER 40–120








Depression Rating Scale, OC
observed cases, SD standard
deviation
a Week 0 of the open-label
study corresponds to the final
visit in the double-blind lead-in
study
b CGI-I rating was based on
baseline of the respective
double-blind lead-in study
Efficacy measure Mean (SD)
MADRS total score Baseline of double-blind lead-in study 35.9 (4.1)
LOCF Change from baseline (lead-in) to open-label week 0a -13.5 (10.7)
Change from week 0a to week 48 -10.0 (11.6)
Change from baseline (lead-in) to week 48 -23.6 (10.8)
OC Change from baseline (lead-in) to open-label week 0a -13.5 (10.7)
Change from week 0a to week 48 -13.3 (10.9)
Change from baseline (lead-in) to week 48 -27.6 (8.5)
CGI-S Baseline of double-blind lead-in study 4.8 (0.6)
LOCF Change from baseline (lead-in) to open-label week 0a -1.3 (1.3)
Change from baseline (lead-in) to week 48 -2.5 (1.4)
OC Change from baseline (lead-in) to open-label week 0a -1.3 (1.3)
Change from baseline (lead-in) to week 48 -3.0 (1.1)
CGI-Ib
LOCF Score at week 48 1.9 (1.1)
OC Score at week 48 1.5 (0.8)
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weight loss from baseline to endpoint (-0.55 kg) was
observed and only one patient (0.1 %) discontinued the
study due to weight gain. PCS changes in transaminases
and liver function tests, metabolic parameters, vital signs,
and ECG were generally small and not clinically mean-
ingful; no patient met the criteria for Hy’s Law, a reas-
suring finding in a long-term study.
As noted in the baseline demographic characteristics of
the study population, 54 % of patients had a lifetime his-
tory of suicidal ideation and 22 % had a history of suicidal
behavior as determined by the C-SSRS. During the
extension study, suicidality was assessed by both the
C-SSRS and investigator-determined suicide-related TE-
AEs, which are different types of measures that may yield
somewhat discrepant results. The C-SSRS was completed
by the patient via an interactive voice response system at
every visit; responses were evaluated at that visit for sui-
cidal ideation and behavior that occurred since the last
visit. Information collected from the C-SSRS, clinical
progress notes, and other rating scales administered during
the study (e.g., MADRS) were also reviewed and evaluated
by the investigator as part of the overall assessment of
suicidality; the totality of this information was used to
determine if an event needed to be recorded as a TEAE. In
the extension study, the incidence of TEAEs related to
suicidal ideation, behavior, or attempt was low; TEAEs of
aborted suicide attempt and actual attempt were reported in
two patients each. C-SSRS–based suicidal ideation was
reported in 22 % of patients, most in the least severe cat-
egory, and suicidal behavior was reported in three patients
(one attempt and two aborted attempts). Each suicide event
should be interpreted within the context of the method used
to report it.
Although the primary objective of this open-label study
was to evaluate the long-term safety and tolerability of
levomilnacipran ER, efficacy assessments were collected
and summaries were provided; no inferential statistics were
performed. Without a placebo or active-control group for
comparison, no conclusion regarding the efficacy of levo-
milnacipran ER in long-term use can be made. Neverthe-
less, it should be noted that MADRS and CGI-S scores
decreased over the course of the study. For patients who
completed the study, approximately 90 % responded to
treatment and almost 70 % achieved remission. Some
discontinuity in treatment effect may have occurred during
the double-blind down-titration period since all patients
were removed from treatment at this time.
5 Conclusion
A good safety and tolerability profile is especially impor-
tant for antidepressant agents since extended treatment may
be prescribed and patients often discontinue antidepressant
medications earlier than recommended. Although the lack
of placebo control limits the ability to assess the cause of
change in an open-label study, the findings in this 48-week
extension study of levomilnacipran ER supported the
safety and tolerability findings that were observed in
patients who completed a short-term double-blind lead-in
study.
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